To investigate metabolic patterns of HER2-positive breast cancer patients with different trastuzumab response, we obtained and analyzed the plasma metabolites data of both trastuzumab-sensitive and primary-resistant patients (26/26) with good interclass correlations (Figure 1—figure supplement 1A–C). The gene discussed is ERBB2; the disease is breast cancer.